Literature DB >> 16498342

[Guidelines on intestinal dysmicrobism (SIBO Small Intestine Bacterial Overgrowth)].

P F Bayeli1, M Mariottini, L Lisi, P Ferrari, F Tedone.   

Abstract

Bacterial flora consisting of Gram-positive and Gram-negative germs, aerobes and anaerobes, is distributed along the digestive tract in varying quantities from zero to a maximum of 10(12)/ml of endoluminal aspirate. This bacterial ecosystem counterbalances with the ecological niche of the host organism and harmonizes with the various digestive, secretory, motor, absorption and sensitivity functions of the entire intestine. This dynamic equilibrium between environment, bacterial flora and host may be interrupted due to a variety of complex reasons, leading to quantitative and qualitative modifications of the normal intestinal microbial flora that can cause Small Intestinal Bacterial Overgrowth (SIBO). SIBO is thus due to an invasion of the small intestine, from the upper part, by pathogenic strains of oro-alimentary origin, and from the lower part by colo-fecal germs through an incontinent Bauhin's valve. These germs alter the normal intestinal functions and give rise to a form of diarrhoea in which the characteristics of malabsorption prevail, with all the inherent diagnostic problems. The diagnostic gold standard is the culture of the duodenal-jejunal aspirate which, being difficult to perform and providing unreliable results, is not easily included in the daily clinical routine. Indirect tests include the breath test, which is widely accepted by patients but burdened by diagnostic doubts on the part of medical personnel. Diagnostic confirmation is therefore greatly conditioned by clinical subjectivity and objectivity, as well as by the response to medical therapy. In cases of declared malabsorption, medical therapy is necessary by means of appropriate diet, prebiotics, probiotics and antibiotics. The difficulty in identifying the specific bacterial population and the part of the digestive tract that is affected indicate the appropriateness of a broad-spectrum antibiotic therapy, capable of eradicating aerobes and anaerobes, preferably with a topical rather than a general action, frequently cause of undesired effects.

Entities:  

Year:  1999        PMID: 16498342

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  4 in total

1.  Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.

Authors:  Sergio Peralta; Claudia Cottone; Tiziana Doveri; Piero Luigi Almasio; Antonio Craxi
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

2.  Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics.

Authors:  I Esposito; A de Leone; G Di Gregorio; S Giaquinto; L de Magistris; A Ferrieri; G Riegler
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

3.  Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.

Authors:  Doron Boltin; Tsachi Tsadok Perets; Einav Shporn; Shoshana Aizic; Sigal Levy; Yaron Niv; Ram Dickman
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-10-17       Impact factor: 3.944

4.  Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection.

Authors:  Paulina Konrad; Jan Chojnacki; Anita Gąsiorowska; Cezary Rudnicki; Aleksandra Kaczka; Cezary Chojnacki
Journal:  Prz Gastroenterol       Date:  2018-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.